Product NDC: | 0409-3508 |
Proprietary Name: | Imipenem and Cilastatin |
Non Proprietary Name: | IMIPENEM and CILASTATIN SODIUM |
Active Ingredient(s): | 250; 250 mg/100mL; mg/100mL & nbsp; IMIPENEM and CILASTATIN SODIUM |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0409-3508 |
Labeler Name: | Hospira, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA090825 |
Marketing Category: | ANDA |
Start Marketing Date: | 20111117 |
Package NDC: | 0409-3508-10 |
Package Description: | 25 VIAL in 1 CARTON (0409-3508-10) > 100 mL in 1 VIAL |
NDC Code | 0409-3508-10 |
Proprietary Name | Imipenem and Cilastatin |
Package Description | 25 VIAL in 1 CARTON (0409-3508-10) > 100 mL in 1 VIAL |
Product NDC | 0409-3508 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | IMIPENEM and CILASTATIN SODIUM |
Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20111117 |
Marketing Category Name | ANDA |
Labeler Name | Hospira, Inc. |
Substance Name | CILASTATIN SODIUM; IMIPENEM |
Strength Number | 250; 250 |
Strength Unit | mg/100mL; mg/100mL |
Pharmaceutical Classes | Carbapenems [Chemical/Ingredient],Penem Antibacterial [EPC],Dipeptidase Inhibitors [MoA],Renal Dehydropeptidase Inhibitor [EPC] |